Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q3 2025 · 10-Q
Revenue$5.07B$5.07B+20.3% vs Q3 2024 Net Income$755.00M$755.00M+61.3% vs Q3 2024 EPS Diluted$0.51$0.51+59.4% vs Q3 2024 Gross Profit$3,542,000,000+22.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,343,000,000+34.0% Free Cash Flowderived$1,162,000,000+41.2% Margins · derivedGross margin69.9%+1.1 pt vs Q3 2024
Operating margin20.7%+3.3 pt vs Q3 2024
Net margin14.9%+3.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 3, 2025 · 34 d after period end